About Us

We’re Cyted – a pioneering gastrointestinal health diagnostics company enabling early access and detection for esophageal cancer and Barrett’s esophagus.

Our technology brings a minimally invasive diagnostic approach to market – our EndoSign test combines a swallowable pill‑like device with advanced biomarkers and analytics to help detect disease earlier and faster. What started as an idea between a health‑tech entrepreneur and leading clinical scientists at Cambridge University has quickly grown into an international company operating across the UK and US, backed by investors such as EQT Life Sciences and a $44M Series B investment.

We still work like a startup – because we are one. Things move quickly here and we build as we go. Some days you’ll be solving problems first of their kind with innovative approaches. Other days you’ll just need to roll your sleeves up and get things done. That’s the reality of building a company that’s growing fast...